相关临床试验
93
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1989
已完成
72
77.4%
尚未招募
2
2.1%
招募中
3
3.2%
终止
10
10.8%
Unknown
1
1.1%
撤回
5
5.4%
暂无批准数据
- ResMed's NightOwl, an FDA-cleared home sleep apnea test utilizing fingertip sensor technology, is now available nationwide to simplify obstructive sleep apnea diagnosis from patients' homes. - The disposable device records up to 10 nights of sleep data, uses auto-scoring algorithms validated against polysomnography, and integrates with ResMed's digital ecosystem to streamline diagnostic workflows. - With obstructive sleep apnea affecting nearly one billion people globally and 80% of cases remaining undiagnosed, NightOwl addresses a critical need for accessible testing as recent research shows CPAP therapy can significantly reduce mortality risk.
- Incannex Healthcare has appointed sleep medicine expert Dr. Alison Wimms to their newly formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board, strengthening their clinical development expertise. - IHL-42X, a novel oral combination of acetazolamide and dronabinol, demonstrated promising results in Phase 2 trials with up to 51% reduction in Apnea-Hypopnea Index. - The company is advancing a global Phase 2/3 'RePOSA' clinical trial, with top-line results from the U.S. Phase 2 portion expected in first half of 2025.
- The ADVENT-HF trial demonstrated that peak flow-triggered adaptive servo-ventilation (ASV) devices improved sleep quality and quality of life in heart failure patients. - Unlike the SERVE-HF trial, ADVENT-HF did not find an increased risk of mortality with ASV use; mortality trended lower, though not statistically significant. - The study highlights that ASV devices are not generic, with efficacy and safety varying based on manufacturer-specific algorithms and triggering mechanisms. - ADVENT-HF used Philips Respironics BiPAP autoSV Advanced, which differs from the minute ventilation-triggered ASV used in SERVE-HF, potentially explaining the divergent outcomes.
